PF-00489791

Unknown / undisclosed

DiscontinuedPhosphodiesterase type 5 (PDE5)No recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued, for reasons the sponsor has not stated

PF-00489791 was Pfizer’s PDE5 inhibitor. Its registered studies were in Raynaud’s phenomenon, diabetic nephropathy, pulmonary arterial hypertension, high blood pressure and post-herpetic neuralgia, plus a healthy-volunteer study. Pfizer’s own text on the terminated study NCT00853112 attributes the stop to a change in the compound’s development rather than to safety. The programme itself then ended: PF-00489791 is listed under Cardiovascular/Metabolics in the Pfizer pipeline filed with the SEC on 28 April 2014 (exhibit 99.6 to Pfizer’s 8-K, accession 0001193125-14-161303), no SEC filing has named it since May 2014, and Pfizer’s current pipeline page (pfizer.com/science/drug-product-pipeline, updated 4 August 2026) enumerates every investigational medicine by phase and therapy area without it. No reason for the programme stop is stated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (5)
Other / comorbidity
NCT01200394 · Pfizer
2010-12 – 2013-08 · Diabetic Nephropathies
What this study did
NCT01090492 · Pfizer
2010-08-04 – 2011-05-31 · Raynaud's Disease, Peripheral Vascular Disease
What this study did
NCT00599638 · Pfizer
2008-04-09 – 2008-12-23 · Postherpetic Neuralgia
What this study did
NCT00422461 · Pfizer
2007-02-27 – 2008-01-28 · Hypertension
What this study did
Phase 1 (1)

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.